In HT-29 and U937 cells, SM-164 was used with TNFα and the caspase inhibitor zVAD to trigger cell death. Phenhydan suppressed death and associated necroptosis-pathway phosphorylation in this combination model. These findings describe a conditional combination response and do not establish SM-164-alone cytotoxicity. [3]
Competitive binding to XIAP containing BIR2 and BIR3
Biochemical assay · Recombinant human XIAP residues 120–356; competitive displacement of Smac-1F tracer. [1]
Compound 4 (SM-164) displaced the tracer with IC50 1.39 ± 0.17 nM (SD). The stereoisomer 6 was weaker (71.5 ± 34.9 nM), and inactive control 5 had IC50 >100,000 nM. This is a binding-assay endpoint, not a cellular treatment dose or Ki.
Literature-Reported Treatment Conditions
- Treatment concentration
- Compound concentration series; XIAP 3 nM and Smac-1F 0.5 nM.
- Exposure duration
- 2 h before polarization measurement.
- Method
- Competitive fluorescence polarization; nonlinear least-squares IC50 fitting. XIAP plus tracer and tracer alone define 0% and 100% displacement; AVPI peptide is an assay control.
- Reported limits
- Replicate number for Figure 8 and compound vehicle are not specified in the selected assay description. Final counterion after purification is not established.
Methods and source locations
Compound reported in the paper: SM-164; Compound label in the paper: compound 4 (SM-164)
Applies to the SM-164 material reported in this paper. Catalog SMILES lacks stereochemical specification; final form and Adooq lot equivalence are not established. No salt or dose conversion is made.
Figure 6 compound 4; Figure 8 image/caption and quantitative-binding Results; Experimental compound 4 and XIAP L-BIR2-BIR3 FP assay
Displacement of Smac-1F from XIAP L-BIR2-BIR3: Fluorescence polarization, 2 h incubation; fitted IC50. — Figure 8 image legend; quantitative-binding Results; Experimental FP assay
Cellular cIAP-1 degradation and proteasome-inhibitor control
Cell-based study · Human MDA-MB-231 breast cancer cells; HCT116 colon cancer cells in the MG-132 control comparison. [2]
In MDA-MB-231 cells, SM-164 reduced cIAP-1 after 60 min, with a marked decrease at 1 nmol/L and undetectable levels at 10–100 nmol/L as described by the authors. MG-132 blocked the rapid cIAP-1 loss in both MDA-MB-231 and HCT116 cells. Degradation in HCT116 should not be interpreted as proof of single-agent cell killing.
Literature-Reported Treatment Conditions
- Treatment concentration
- SM-164 0.1, 1, 10 and 100 nmol/L in Figure 3C; 100 nmol/L in Figure 3D,E.
- Exposure duration
- 60 min dose series; 100 nmol/L time course from 5 min to 24 h; MG-132 comparison at 10 min.
- Method
- Western blotting for cIAP-1, XIAP and β-actin; untreated and less-active SM-123/SM-173 controls; comparison with SM-122; MG-132 cotreatment control.
- Co-treatment
- MG-132 proteasome-inhibitor control in Figure 3E; SM-164-alone dose/time series in Figure 3C,D.
- Reported limits
- MG-132 dose and pretreatment duration were not established from the main-text/figure material read. Compound vehicle and final salt are not specified there; SI PDF was not retrieved.
Methods and source locations
Compound reported in the paper: SM-164; Compound label in the paper: SM-164
Applies to the SM-164 material reported in this paper. Catalog SMILES lacks stereochemical specification; final form and Adooq lot equivalence are not established. No salt or dose conversion is made.
Figure 3C-E images/caption; Results “Both SM-164 and SM-122 induce rapid cIAP-1 degradation in cancer cells”; Methods Drugs, Cell lines, Western blot analysis
Cellular cIAP-1 abundance and proteasome dependence: Western blot; β-actin loading control; untreated, analog and inhibitor controls. No densitometric IC50 derived. — Figure 3C-E; corresponding cIAP-1 degradation Results
Phenhydan suppresses death in an SM-164-containing combination
Cell-based study · Human HT-29 and U937 cells; matched FACS and Western-blot samples in Figure 2C,D. [3]
The TNFα/SM-164/zVAD combination caused time-dependent cell death in both human cell models. Phenhydan pretreatment suppressed this response and the associated necroptosis-pathway phosphorylation. The study tests combination-induced death and its inhibition; it does not quantify SM-164-alone efficacy.
Literature-Reported Treatment Conditions
- Treatment concentration
- SM164 1 µM; TNFα 100 ng/ml; zVAD 25 µM; Phenhydan 1 mM where indicated.
- Exposure duration
- Up to 8 h stimulation at 37 °C; Phenhydan added 30 min beforehand.
- Method
- Annexin V/7-amino-actinomycin D flow cytometry; paired immunoblots for RIPK1, RIPK3, MLKL and phosphorylated proteins; β-actin loading control.
- Vehicle
- Vehicle comparator indicated in figure; composition not specified in selected material.
- Co-treatment
- TNFα + SM164 + zVAD (TSZ), with or without Phenhydan.
- Reported limits
- No SM164-alone arm in the selected design. Counterion, catalog number and lot were not reported in the selected reagent description.
Methods and source locations
Compound reported in the paper: SM-164; Compound label in the paper: SM-164
Applies to the SM-164 material reported in this paper. Catalog SMILES lacks stereochemical specification; final form and Adooq lot equivalence are not established. No salt or dose conversion is made.
Figure 2C,D image and full caption; Results initial Phenhydan section; Methods Cell lines, Reagents and antibodies, Assessment of cell death in vitro, Analysis of cell death by western blotting
Death induced by TSZ and inhibited by Phenhydan: Annexin V/7-AAD FACS. No exact percentages inferred from bars. — Figure 2C,D image/caption
Necroptosis-pathway activation in the matched cell samples: Western blot on split samples also used for FACS; total-protein and β-actin controls. — Figure 2C,D image/caption